CytoSorbents Reports Q2 Revenue of $9.6M, Adjusted EPS of 5c, and Initiates German Commercial Reorganization

CytoSorbents reports Q2 adjusted EPS of 5c, in line with last year. Revenue reached $9.6M, exceeding the consensus estimate of $9.22M. CEO Phillip Chan attributed the strong performance to sales growth in Germany and other direct sales territories. The company initiated a reorganization of its German commercial team and sales approach, leading to a temporary disruption in Q1. The CEO remains confident that the reorganization will lead to stronger execution, improved performance, and more robust sales growth in the future.

CytoSorbents Corporation (NASDAQ: CTSO) has reported its Q2 2025 financial results, with revenue growing by 9% to $9.62 million, surpassing analyst expectations of $9.23 million [1]. The company's adjusted earnings per share (EPS) of 5 cents were in line with last year's adjusted EPS of -$0.05, meeting analyst expectations [1].

The strong performance was driven by a 22% year-over-year sales growth in Germany, which accounted for a significant portion of the revenue increase [1]. The company attributed this growth to the reorganization of its German commercial team, which led to improved sales performance [1].

The reorganization, which resulted in a temporary disruption in Q1, is now showing positive results. CEO Phillip Chan expressed confidence that the changes will lead to stronger execution and more robust sales growth in the future [1].

CytoSorbents is focused on improving gross margins and controlling costs to achieve near breakeven by the end of 2025. The company is also confident in resolving Health Canada regulatory issues [1].

Analysts remain bullish on the company, with an average rating of "buy" and a consensus recommendation for the advanced medical equipment & technology peer group of "buy" [1]. The median 12-month price target for Cytosorbents Corp is $4.00, about 77.5% above its August 6 closing price of $0.90 [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLXDCD52C:0-medical-devices-firm-cytosorbents-q2-revenue-beats-estimates/